Dr. Urmi Roy, Global Product Manager for Flow Cytometry Reagents, Miltenyi Biotec, explains why immunogenicity prediction is a key consideration for therapeutic development. Biologic drugs as therapy have improved the treatment of many diseases, but their success is often tempered by antidrug antibodies (ADAs), which specifically recognise the therapeutic molecule as a foreign antigen. Often clinically benign, ADAs […]
Menu ≡ ╳ 
